Navigation Links
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Date:6/8/2012

BERLIN, June 8, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA). The results were presented as a late-breaking oral presentation at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology [EULAR abstract LB0005: 12-Week Results of a Phase IIb Dose-Ranging Study of LY3009104 (INCB028050), an Oral JAK1/JAK2 Inhibitor, in Combination with Traditional DMARDs in Patients with Rheumatoid Arthritis].

The Phase IIb randomized double-blind, placebo-controlled, dose-ranging study, known as JADA, involved a total of 301 patients with active RA on stable doses of methotrexate. Patients were randomized to receive either placebo or one of four once-daily doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) for 12 weeks.

Primary Endpoint Achieved

The Phase IIb trial achieved the primary endpoint by demonstrating a statistically significant difference in the American College of Rheumatology 20 (ACR20) response between the combined 4 mg and 8 mg baricitinib groups (76 percent) compared with placebo (41 percent) after 12 weeks of treatment (p<0.001). Statistically significant improvement was observed at the first assessment point after two weeks of treatment and was sustained through week 12.

Summary of Secondary Endpoints

A statistically significant difference in response for the ACR20, ACR50 and ACR70 secondary endpoints was observed with the 1 mg, 4 mg and 8 mg dose groups compared with placebo.

ACR20

  • 8 mg: 78 percent (p<0.001)
  • 4 mg: 75 percent (p<0.001)
  • 2 mg: 54 percent (
    '/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
2. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. DiversityInc Names Lilly a Top Company for Diversity
7. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
8. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
11. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHAPEL HILL, N.C. , Jan. 23, 2015 For ... organizations are in dealing with payers. Likewise, the importance of ... payers - will only continue to grow as payer formularies ... patients access therapies. At the same time, managed ...
(Date:1/23/2015)... LOS ANGELES , Jan. 23, 2015 A lot ... the best methods for treating  certain illnesses, injuries, or conditions. ... to replace previous treatment methods with ones that they consider ... treating hernias, there is not one textbook method of treatment ...
(Date:1/23/2015)... 23, 2015  A new analysis of Centers for Medicare ... data shows that 81 percent of seniors chose lower-cost ... discounts at certain pharmacies. The findings were released by ... are now the foundation of Medicare Part D," said ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... A milestone in lupus research was met this weekend!  On ... held its 8th annual New York City Walk with Us ... matched by the enthusiasm of the nearly 3000 walkers in attendance ... master of ceremonies, My9 news anchor Brenda Blackmon, ALR Chairman Robert ...
... LOUIS, Oct. 27, 2011 Express Scripts, Inc. (Nasdaq: ... following investor conferences in November: Credit Suisse 2011 ... mountain (9:30 a.m. eastern). Lazard Capital Markets, 8th ... a.m. eastern. These presentations will also be ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2
(Date:1/22/2015)... Houston, TX (PRWEB) January 22, 2015 The ... Pro Bodybuilder Ben Pakulski to increase lean muscle by up ... This has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting ... shows that it is a step-by-step, scientific diet formula that ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... intake in humans can reduce heart disease, according to research ... the first time the connection between a high phosphate diet ... been proven. The findings have been published in Arteriosclerosis, ... research, which was funded by the Sheffield Kidney Association and ...
... 7 (HealthDay News) -- A new study suggests that depressed ... thoughts because they can,t turn their attention to other things. ... relive what happened to them over and over again," said ... an Association for Psychological Science news release. "Even though they ...
... proteins in frog skins which could be used to ... the growth of blood vessels. The award-winning research, led ... has identified two proteins, or ,peptides, which can be ... ,angiogenesis, the process by which blood vessels grow ...
... molecules of RNA a chemical cousin of DNA ... occurs in degenerative eye disorders, UT Southwestern Medical Center researchers ... of the National Academy of Sciences , suggest a potential ... disorder that affects nearly 2 million Americans and is a ...
... , MONDAY, June 6 (HealthDay News) -- America may be ... beginning to believe that plenty may have become too much. ... and a constant barrage from media sources have overloaded Americans ... physical health, according to Mary Jane Rotheram-Borus, a psychology professor ...
... (HealthDay News) -- Many people who suffer from obstructive sleep ... of weight, a new study suggests. Without realizing ... the night as they struggle to breathe. The condition can ... patients are treated with continuous positive airway pressure (CPAP), a ...
Cached Medicine News:Health News:Scientists unlock potential of frog skin to treat cancer 2Health News:Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders 2Health News:Too Much Work, Food, Media May Be Hurting Health 2Health News:Too Much Work, Food, Media May Be Hurting Health 3Health News:Weight Loss May Help Sleep Apnea Symptoms 2
RapidStrep A test is a qualitative test that detects group A,streptococcal antigen. The test is a rapid, in vitro assay. It is,intended for professional use to help diagnose Strep A,infection i...
... caused by the intracellular parasite Toxoplasma gondii ... or by contract with cat,feces containing oocytes. ... be passed to the fetus through the ... is a cause of mortality and malformation.,This ...
... an immunochromatographic in vitro assay,for detection ... infection.,Infectious mononucleosis (IM) is caused by ... is based on detection of,serum antibodies ... the,heterophile antibodies present in the sera ...
Inquire...
Medicine Products: